The cancer drug you can only get with a specific gene mutation is not one drug — it is an entire class of therapies that the FDA will not allow doctors to prescribe unless a genetic test confirms your tumor carries a particular molecular defect. The most striking example is larotrectinib, sold as Vitrakvi, which was approved in November 2018 for any solid tumor anywhere in the body, as long as it harbors an NTRK gene fusion. It does not matter whether the cancer started in the lung, the colon, the thyroid, or the brain. What matters is the mutation. The drug produced tumor responses in 75% of patients, with 22% achieving complete responses and 53% seeing partial responses. NTRK fusions occur in less than 1% of all cancers, which means the vast majority of patients will never qualify — but for those who do, it was a genuine breakthrough. This approach, called tumor-agnostic or mutation-based treatment, has expanded rapidly.
As of the latest FDA data, 22 oncology drugs now require genetic or biomarker testing as part of their prescribing labels. These drugs target specific mutations including KRAS G12C, BRAF V600E, PIK3CA, IDH1/2, and others. If your tumor does not carry the mutation, the drug literally cannot work — in some cases, the molecule is designed to physically lock onto the mutant protein and has no effect on the normal version. This article covers how these drugs work, which mutations they target, how to get tested, and what recent approvals through 2026 mean for patients and their families. For those navigating brain health concerns alongside a cancer diagnosis, the intersection is more relevant than you might expect. One of the newest mutation-specific drugs, vorasidenib, was approved in August 2024 specifically for brain tumors — low-grade gliomas carrying IDH1 or IDH2 mutations. Understanding how genetic testing opens or closes doors to treatment options is increasingly important for anyone managing complex health decisions.
Table of Contents
- Which Cancer Drugs Require a Specific Gene Mutation Before You Can Get Them?
- How Genetic Testing Determines Whether You Qualify for Treatment
- The Brain Cancer Drug That Requires an IDH Mutation
- How to Get Tested and What to Do With the Results
- When Mutation-Specific Drugs Fail or Are Not Enough
- Next-Generation Mutation-Specific Drugs in the Pipeline
- What This Means for the Future of Cancer Treatment and Brain Health
- Conclusion
- Frequently Asked Questions
Which Cancer Drugs Require a Specific Gene Mutation Before You Can Get Them?
The list has grown substantially in the past few years. Larotrectinib and entrectinib both target NTRK gene fusions — entrectinib received FDA approval in August 2019 and also covers ROS1-positive non-small cell lung cancer. Sotorasib, branded as Lumakras, became the first drug to target the KRAS G12C mutation when it was approved in May 2021 for metastatic non-small cell lung cancer. About 13% of NSCLC patients carry this specific G12C mutation, and in clinical trials, tumors shrank in 36% of patients with responses lasting a median of 10 months. The drug works by covalently locking the mutant KRAS protein in its inactive state — a mechanism that is physically impossible without the G12C mutation present. The BRAF V600E mutation is another well-known gatekeeper. The BRAFTOVI (encorafenib) combination received full FDA approval as the only approved targeted regimen for first-line BRAF V600E-mutated metastatic colorectal cancer.
Only about 8 to 12% of colorectal cancer patients carry this specific BRAF mutation, so the majority are not eligible. For comparison, a patient with colorectal cancer who tests negative for BRAF V600E would receive standard chemotherapy combinations instead — a completely different treatment path determined entirely by one molecular test result. This is not a matter of physician preference or hospital protocol. The FDA label itself restricts prescribing to mutation-confirmed patients. More recently, inavolisib, sold as Itovebi, was approved on October 10, 2024 for HR-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer. Again, genetic testing confirming the PIK3CA mutation is a prerequisite. The pattern is consistent across all of these drugs: no confirmed mutation, no prescription.
How Genetic Testing Determines Whether You Qualify for Treatment
The FDA requires what are called companion diagnostic tests before any of these mutation-specific drugs can be prescribed. The two most widely used platforms are FoundationOne CDx and Guardant360 CDx. FoundationOne CDx screens 324 genes across all solid tumor types in a single test, which means one biopsy sample can simultaneously check for NTRK fusions, KRAS mutations, BRAF alterations, PIK3CA changes, and dozens of other actionable targets. Guardant360 CDx works from a blood draw rather than a tissue biopsy, which matters when a tumor is in a location that is difficult or risky to biopsy — such as the brain. However, genetic testing is not without limitations. A negative result does not always mean the mutation is absent. Tumor heterogeneity — where different parts of the same tumor carry different mutations — can lead to false negatives if the biopsy sample misses the mutant region.
Liquid biopsies from blood can sometimes miss mutations that are present at low levels, particularly in brain tumors where the blood-brain barrier limits how much tumor DNA circulates in the bloodstream. If a first test comes back negative but clinical suspicion remains high, oncologists will sometimes recommend retesting with a different method or a repeat biopsy from a different site. There is also the question of timing. Mutations can emerge or change as cancers evolve, particularly after initial treatment. A tumor that tested negative for KRAS G12C at diagnosis might acquire that mutation after chemotherapy. This is why some oncologists recommend repeat genomic profiling at the time of disease progression, not just at initial diagnosis. The mutation that qualifies you for a targeted drug might not be there at the start but could appear later.
The Brain Cancer Drug That Requires an IDH Mutation
For readers of a brain health site, vorasidenib deserves particular attention. Approved by the FDA in August 2024 under the brand name Voranigo, it is specifically indicated for IDH1 or IDH2-mutated low-grade gliomas. The drug was developed based on a discovery at Johns Hopkins, and it represents the first targeted therapy for this subset of brain tumors. Only patients whose gliomas carry IDH mutations are eligible, which immediately divides brain tumor patients into two groups with very different treatment options. IDH mutations are actually more common in lower-grade gliomas than in the aggressive glioblastomas that most people associate with brain cancer.
Roughly 70 to 80% of grade 2 and grade 3 gliomas carry IDH mutations, which means a substantial number of patients with these slower-growing brain tumors may qualify. The significance for patients and families dealing with cognitive and neurological concerns is direct — low-grade gliomas often affect memory, language, and executive function long before they become life-threatening. A drug that can slow or shrink these tumors has implications not just for survival but for preserving cognitive function. The limitation is that vorasidenib does not work for IDH-wildtype gliomas, which include most glioblastomas. A patient diagnosed with an aggressive, IDH-wildtype brain tumor would not benefit from this drug regardless of how much they or their physician might wish otherwise. The molecular test result draws a hard line.
How to Get Tested and What to Do With the Results
If you or a family member receives a cancer diagnosis, the practical first step is to ask the oncologist whether comprehensive genomic profiling has been ordered. Not all oncologists automatically order broad panel testing — some may only test for one or two specific mutations relevant to the cancer type. Requesting a comprehensive panel like FoundationOne CDx ensures that all known actionable mutations are checked at once, which prevents the need for repeated biopsies if additional mutations are later considered. The tradeoff with comprehensive testing is cost and turnaround time. A broad genomic panel can take two to three weeks to return results, and while most major insurers now cover these tests for advanced cancers, coverage for early-stage disease is less consistent.
Some patients pay out of pocket, which can run into several thousand dollars. The alternative — testing for one mutation at a time based on cancer type — is cheaper per test but risks missing mutations that could open doors to treatments the oncologist would not otherwise consider. For cancers like NSCLC, where multiple actionable mutations exist (KRAS G12C, EGFR, ALK, ROS1, RET, MET exon 14 skipping, NTRK, and now HER2/ERBB2), testing one at a time is wasteful and slow. A UC San Diego study published on January 8, 2026 found that individualizing multi-drug treatments based on each patient’s specific tumor mutations significantly enhances treatment success compared to non-personalized approaches. This reinforces the argument for broad testing rather than narrow, single-mutation checks. The more you know about the tumor’s genetic profile, the more precisely treatment can be matched.
When Mutation-Specific Drugs Fail or Are Not Enough
These drugs are not cures for most patients, and that distinction matters. Sotorasib, for example, shrank tumors in 36% of KRAS G12C-mutated lung cancer patients — which means 64% did not see meaningful tumor shrinkage. Even among responders, the median duration of response was 10 months, after which most tumors found ways to grow again. Cancer cells are genetically unstable, and they can develop resistance mutations that bypass the drug’s mechanism. A tumor might lose its KRAS G12C mutation, acquire a secondary mutation that reactivates the same signaling pathway, or switch to an entirely different growth driver. This is why oncologists increasingly think about sequencing and combining mutation-targeted drugs rather than relying on any single agent. However, combining targeted therapies raises the risk of compounding side effects, and not all combinations have been tested in clinical trials.
Patients sometimes face the difficult reality of qualifying for a mutation-specific drug, responding well initially, and then watching the disease progress with fewer remaining options. The mutation that opened a treatment door does not guarantee that door stays open. There is also the challenge of rare mutations. NTRK fusions occur in less than 1% of all cancers. Even with universal genomic testing, the vast majority of patients will never carry a mutation that matches one of these drugs. For caregivers and family members — particularly those already managing dementia or cognitive decline in a loved one — the emotional weight of learning that a mutation-specific drug exists but your family member does not qualify can be significant. It is worth understanding that these drugs represent progress for a subset of patients, not a universal solution.
Next-Generation Mutation-Specific Drugs in the Pipeline
The pipeline continues to expand into new mutations and refine treatments for known ones. Zoldonrasib received FDA breakthrough therapy designation for KRAS G12D-mutated non-small cell lung cancer, targeting a different KRAS mutation than sotorasib. This matters because KRAS G12D is actually more common than G12C in certain cancer types, including pancreatic cancer, and until now there has been no approved drug targeting it.
Sevabertinib also received breakthrough therapy designation in January 2026 for NSCLC with HER2 (ERBB2) activating mutations, addressing another molecular subgroup that previously lacked a tailored option. On the breast cancer side, the FDA accepted Genentech’s application for giredestrant on February 19, 2026, for ESR1-mutated, ER-positive advanced breast cancer, with a decision expected by December 18, 2026. ESR1 mutations frequently emerge as a resistance mechanism in breast cancers treated with standard hormonal therapies, so this drug could provide an option for patients whose tumors have evolved past first-line treatment. Each of these approvals and designations adds another mutation to the list of molecular keys that unlock specific treatments.
What This Means for the Future of Cancer Treatment and Brain Health
The trajectory is clear: cancer treatment is moving toward a model where the first question is not “where is the tumor?” but “what mutations does it carry?” For brain health specifically, the vorasidenib approval for IDH-mutated gliomas sets a precedent that may extend to other brain tumor subtypes as more targetable mutations are identified. Researchers are actively investigating whether mutations in genes like TERT, ATRX, and TP53 — all commonly altered in brain tumors — could be similarly exploited with mutation-specific drugs. For patients and families already navigating cognitive health challenges, this genetic approach to treatment carries a broader lesson.
Just as brain tumor treatment is becoming more personalized through molecular profiling, neurodegenerative disease research is increasingly exploring genetic risk factors and potential gene-targeted interventions. The infrastructure being built for cancer genomics — the testing platforms, the companion diagnostics, the FDA frameworks for mutation-specific approvals — may eventually serve neurology in similar ways. The science is not there yet for most neurological conditions, but the model being proven in oncology is the likely template.
Conclusion
Cancer drugs that require a specific gene mutation represent one of the most consequential shifts in modern medicine. From larotrectinib’s approval for NTRK fusions in 2018 to vorasidenib’s approval for IDH-mutated brain tumors in 2024 and the breakthrough designations of 2026, the list of mutation-gated treatments now spans 22 oncology drugs covering mutations in ALK, BRAF, EGFR, KRAS, NTRK, PIK3CA, IDH, and others. For patients, the actionable takeaway is straightforward: ask for comprehensive genomic testing at diagnosis, and ask again at progression if the disease evolves.
For families managing complex health situations — especially those balancing cancer treatment with cognitive health concerns like dementia caregiving — understanding this landscape helps with informed decision-making and realistic expectations. Not every patient will carry an actionable mutation, and not every mutation-matched drug will produce a lasting response. But the option should never be missed because testing was not performed. The molecular profile of a tumor is now as important as its location, and knowing what mutations are present is the first step toward knowing what treatments are on the table.
Frequently Asked Questions
How do I know if my cancer has a treatable gene mutation?
Your oncologist can order comprehensive genomic profiling through tests like FoundationOne CDx, which screens 324 genes across all solid tumor types, or Guardant360 CDx, which works from a blood sample. These companion diagnostic tests are required by the FDA before mutation-specific drugs can be prescribed.
Does insurance cover genetic testing for cancer mutations?
Most major insurers now cover broad genomic profiling for advanced or metastatic cancers. Coverage for early-stage cancers is less consistent and may require prior authorization. Out-of-pocket costs can reach several thousand dollars if coverage is denied, though some testing companies offer financial assistance programs.
Can a cancer develop a new mutation that makes it eligible for a targeted drug?
Yes. Tumors evolve genetically over time and especially after treatment. A cancer that tested negative for a specific mutation at diagnosis may acquire it later. This is why oncologists sometimes recommend repeat genomic profiling when a cancer progresses, rather than relying solely on the original test results.
What happens if my tumor has the right mutation but the drug does not work?
Response rates for mutation-specific drugs vary widely. Larotrectinib shows a 75% response rate in NTRK fusion-positive tumors, while sotorasib produces tumor shrinkage in 36% of KRAS G12C-mutated lung cancers. Even among responders, resistance typically develops over months. Your oncologist would then consider alternative treatments, clinical trials, or combination approaches.
Are there mutation-specific drugs for brain tumors?
Yes. Vorasidenib (Voranigo) was approved in August 2024 for low-grade gliomas carrying IDH1 or IDH2 mutations. It is currently the only FDA-approved targeted therapy for this specific brain tumor mutation. Other brain tumor mutations are under active investigation for potential targeted treatments.
How rare are actionable gene mutations in cancer patients?
It depends heavily on the cancer type. NTRK fusions occur in less than 1% of all cancers. KRAS G12C mutations are found in about 13% of non-small cell lung cancers. BRAF V600E mutations appear in roughly 8 to 12% of colorectal cancers. IDH mutations are found in 70 to 80% of low-grade gliomas. Comprehensive testing is the only way to know if a specific tumor carries any actionable mutation.
